GlassScriptPhysician profile
Amandeep Singh
NPI 1841509874
$112,838.02
in general payments reported to CMS, 2019-2025
31 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,884 · 2020: $99.00 · 2021: $65.98 · 2022: $57K · 2023: $52K · 2024: $292 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $50K · Food and Beverage: $2,237 · Travel and Lodging: $1,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $50,000.00 |
| Food and Beverage | $2,236.92 |
| Travel and Lodging | $1,024.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $40,000.00 | 2022 | |
| Cook Incorporated | $40,000.00 | 2023 | |
| Boston Scientific Corporation | $23,755.99 | 2022-2024 | Resolution 360 Clip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,780.90 | 2022 | |
| Intercept Pharmaceuticals, INC. | $2,656.87 | 2019-2023 | Ocaliva |
| Abbvie INC. | $628.49 | 2021-2025 | Linzess, Creon, Viberzi |
| Medtronic, INC. | $401.16 | 2022-2025 | Nexpowder, V-Loc 180 |
| Janssen Pharmaceuticals, INC | $234.79 | 2022-2023 | Xarelto |
| Janssen Biotech, INC. | $154.70 | 2020-2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $150.40 | 2019-2022 | |
| Genzyme Corporation | $117.33 | 2025 | |
| Shionogi INC | $109.98 | 2019 | |
| Ardelyx, INC. | $99.21 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.07 | 2019-2023 | Trulance |
| Madrigal Pharmaceuticals | $82.28 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $76.80 | 2025 | |
| Baxter Healthcare | $60.57 | 2022 | |
| Celltrion USA INC. | $54.21 | 2025 | Vegzelma |
| Qol Medical, LLC | $48.99 | 2025 | Sucraid |
| Cranial Technologies, INC | $48.34 | 2023-2024 | Doc Band |
| Regeneron Healthcare Solutions, INC. | $47.06 | 2022 | |
| Olympus America INC. | $32.40 | 2024 | Hanarostent Esophagus Tts(Ccc) |
| Nestle Healthcare Nutrition INC. | $31.89 | 2023 | |
| Lilly USA, LLC | $26.35 | 2025 | Omvoh |
| Recordati_rare_diseases_inc. | $25.49 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $23.75 | 2025 | Cold Snares |
| Novartis Pharmaceuticals Corporation | $20.66 | 2022 | |
| Apollo Endosurgery US INC | $20.38 | 2023 | X-Tack Endoscopic Helix Tacking System |
| Phathom Pharmaceuticals, INC. | $20.37 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $16.95 | 2023 | Dificid |
| Braintree Laboratories, INC. | $16.64 | 2025 | Sutab, Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amandeep Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.